| 45.3 -3.06 (-6.33%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 54.4 |
1-year : | 58.7 |
| Resists | First : | 46.57 |
Second : | 50.25 |
| Pivot price | 47.02  |
|||
| Supports | First : | 40.61 |
Second : | 33.79 |
| MAs | MA(5) : | 47.81 |
MA(20) : | 46.04 |
| MA(100) : | 54.52 |
MA(250) : | 63.43 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 56.5 |
D(3) : | 70.5 |
| RSI | RSI(14): 46.1 |
|||
| 52-week | High : | 98.88 | Low : | 40.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EXAS ] has closed above bottom band by 25.2%. Bollinger Bands are 38.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 49.43 - 49.68 | 49.68 - 49.89 |
| Low: | 44.68 - 44.93 | 44.93 - 45.13 |
| Close: | 44.94 - 45.33 | 45.33 - 45.64 |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Fri, 26 Jul 2024
Exact Sciences (NASDAQ:EXAS) Shares Down 3% - MarketBeat
Fri, 26 Jul 2024
Exact Sciences faces headwinds after Medicare panel meeting - Investing.com
Fri, 26 Jul 2024
Exact Sciences pressured as Medicare panel cools on Cologuard Plus price increase - Seeking Alpha
Fri, 26 Jul 2024
Exact Sciences Corporation (NASDAQ:EXAS) is largely controlled by institutional shareholders who own 86% of the company - Simply Wall St
Thu, 25 Jul 2024
CANADA LIFE ASSURANCE Co Acquires 10,356 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Wed, 24 Jul 2024
Mitsubishi UFJ Trust & Banking Corp Sells 106,107 Shares of Exact Sciences Co. (NASDAQ:EXAS) - Defense World
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 185 (M) |
| Shares Float | 183 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 90.2 (%) |
| Shares Short | 14,210 (K) |
| Shares Short P.Month | 8,780 (K) |
| EPS | -1.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.04 |
| Profit Margin | -9.5 % |
| Operating Margin | -15.2 % |
| Return on Assets (ttm) | -3.2 % |
| Return on Equity (ttm) | -7.8 % |
| Qtrly Rev. Growth | 5.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 13.71 |
| EBITDA (p.s.) | -0.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 112 (M) |
| Levered Free Cash Flow | 51 (M) |
| PE Ratio | -34.59 |
| PEG Ratio | -0.5 |
| Price to Book value | 2.65 |
| Price to Sales | 3.3 |
| Price to Cash Flow | 74.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|